Table 2 Demographic characteristics
From: Therapy of chronic hepatitis C in people who inject drugs: focus on adherence
PWID group (N = 101) | Control group (N = 177) | p | |
|---|---|---|---|
Male sex | 66 (65.3%) | 91 (51.4%) | 0.02 |
Age (years, median, range) | 40 (22–68) | 59 (22–87) | < 0.001 |
Foreigners | 12 (11.9%) | 37 (20.9%) | N. S. |
Mode of transmission | |||
Intravenous drug use | 101 (100%) | < 0.001 | |
Blood transfusion | 49 (27.7%) | ||
Tattoo | 11 (62%) | ||
Sexual transmission | 2 (1.1%) | ||
Nosocomial acquisition | 16 (9.0%) | ||
Professional exposure | 13 (7.4%) | ||
Men having sex with men | 4 (2.3%) | ||
Unknown | 82 (46.3%) | ||
Abstinence | |||
Recent or ongoing drug use | 19 (18.8%) | N. A | |
> 1 year | 24 (23.8%) | ||
> 5 years | 58 (57.4%) | ||
Opioid substitution therapy | |||
Methadone | 2 (2%) | N. A | |
Buprenorphine | 0 (0%) | ||
HCV genotype | |||
1a | 34 (33.7%) | 13 (7.3%) | < 0.001 |
1b | 45 (44.5%) | 148 (83.7%) | |
3 | 19 (18.8%) | 13 (7.3%) | |
Other | 3 (3%) | 3 (1.7%) | |
Baseline HCV RNA (IU/mL, median, range) | 763,000 (35–13,500,000) | 1,340,000 (912–24,900,000) | 0.04 |
Fibrosis stage (Metavir score) | |||
F0–F1 | 41 (40.6%) | 72 (40.7%) | |
F2 | 27 (26.7%) | 29 (16.4%) | 0.02 |
F3 | 13 (12.9%) | 14 (7.9%) | |
F4 | 20 (19.8%) | 62 (35.0%) | |